Some things have changed since January 2020, when Frazier Life Sciences closed its 10th venture capital fund, totaling $617m, but much remains the same now that the firm has raised its 11th fund, totaling $987m. Despite the macroeconomic and global political issues causing havoc in the public financing market, scientific innovations continue to generate ideas for new start-ups that many investors are eager to finance in anticipation that big pharma companies eventually will buy them.
Frazier Sees Opportunity For New $987m Fund Despite Financial Market Turmoil
Start-Ups, Growth-Stage And Public Investments All Targeted
Frazier Life Sciences managing partner James Topper described how the firm will use its 11th fund to launch new companies, support growing firms and take advantage of public market opportunities.
More from Financing
• By
Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Public Company Edition: Stock valuations are falling due to political, economic and regulatory uncertainty, resulting in fewer large public offerings, more alternative financings and cost cuts. Carisma, Tenaya, BioAtla, Arbutus, Nkarta, Alector and Adaptimmune announced layoffs.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.